Biosimilar infliximab administration for the management of acute graft-versus-host disease.

Tollkuci E, Fitzpatrick P, Seddon AN, Myers R, Nathan S, Ustun C. Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020:1078155220920681.